Menghui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Menghui Liu has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Xiaodong Zhuang
Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University , 58 Zhongshan 2nd Road, Guangzhou 510080
19 shared publications - Xinxue Liao
Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
16 shared publications - Lichun Wang
Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University , No. 58 Zhongshan Road 2, 510000 Guangzhou
8 shared publications Shaozhao Zhang
Cardiology Department, the First Affiliated Hospital of Sun Yat-Sen University
7 shared publicationsYue Guo
Department of Cardiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
7 shared publications- Shaozhao Zhang
Cardiology Department The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
6 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
Transcatheter edge-to-edge repair in dynamic severe functional mitral regurgitation: A multicentre, randomised, controlled trial
Background: Functional mitral regurgitation (FMR) is a highly dynamic disease. Some patients exhibit only moderate (2+) FMR at rest, which deteriorates to moderate-to-severe or severe FMR (3+ or 4+) during stress, with effective regurgitant orifice area (EROA) increased ≥0.1 cm2—termed dynamic severe FMR. Observational studies link this condition to worse outcomes, with mitral valve intervention offering potential benefits; however, high-quality evidence remains deficient. Aims: The Transcatheter edge-to-edge repair In dynaMic sEvere functional mitral Regurgitation (TIMER) trial aims to assess the safety and effectiveness of transcatheter edge-to-edge repair plus guideline-directed medical therapy versus guideline-directed medical therapy alone in symptomatic chronic heart failure patients with dynamic severe FMR, defined as moderate (2+) regurgitation at rest (EROA ≥0.2 cm2 to <0.3 cm2 and/or regurgitant volume (RVol) ≥30 mL/beat to <45 mL/beat), deteriorating to moderate-to-severe or severe (3+ or 4+) during handgrip stress echocardiography (stress EROA ≥0.30 cm2 and/or RVol ≥45 mL/beat), with EROA increased ≥0.1 cm2. Methods: This prospective, multicentre, randomised trial enrols patients with dynamic severe FMR confirmed by a core laboratory using handgrip stress echocardiography, across 20 participating centres in China. Patients are randomised 1:1 to transcatheter edge-to-edge repair plus medical therapy or medical therapy alone. The primary endpoint is the composite incidence of cardiovascular death and all heart failure hospitalisations during the entire follow-up period. Conclusion: This trial will provide critical evidence on transcatheter edge-to-edge repair in patients with dynamic severe FMR, informing future treatment recommendations. Trial registration number: NCT07197021
- 7 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
Open AccessTranscatheter edge-to-edge repair in dynamic severe functional mitral regurgitation: A multicentre, randomised, controlled trial
Background: Functional mitral regurgitation (FMR) is a highly dynamic disease. Some patients exhibit only moderate (2+) FMR at rest, which deteriorates to moderate-to-severe or severe FMR (3+ or 4+) during stress, with effective regurgitant orifice area (EROA) increased ≥0.1 cm2—termed dynamic severe FMR. Observational studies link this condition to worse outcomes, with mitral valve intervention offering potential benefits; however, high-quality evidence remains deficient. Aims: The Transcatheter edge-to-edge repair In dynaMic sEvere functional mitral Regurgitation (TIMER) trial aims to assess the safety and effectiveness of transcatheter edge-to-edge repair plus guideline-directed medical therapy versus guideline-directed medical therapy alone in symptomatic chronic heart failure patients with dynamic severe FMR, defined as moderate (2+) regurgitation at rest (EROA ≥0.2 cm2 to <0.3 cm2 and/or regurgitant volume (RVol) ≥30 mL/beat to <45 mL/beat), deteriorating to moderate-to-severe or severe (3+ or 4+) during handgrip stress echocardiography (stress EROA ≥0.30 cm2 and/or RVol ≥45 mL/beat), with EROA increased ≥0.1 cm2. Methods: This prospective, multicentre, randomised trial enrols patients with dynamic severe FMR confirmed by a core laboratory using handgrip stress echocardiography, across 20 participating centres in China. Patients are randomised 1:1 to transcatheter edge-to-edge repair plus medical therapy or medical therapy alone. The primary endpoint is the composite incidence of cardiovascular death and all heart failure hospitalisations during the entire follow-up period. Conclusion: This trial will provide critical evidence on transcatheter edge-to-edge repair in patients with dynamic severe FMR, informing future treatment recommendations. Trial registration number: NCT07197021
- Open Access
- 4 July 2026
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 16 (1)
Subgroup-specific cardiovascular effects of intensive lifestyle intervention: a causal forest analysis in adults with type 2 diabetes and overweight/obesity
To evaluate the heterogeneity of treatment effects (HTEs) of intensive lifestyle intervention (ILI) in adults with type 2 diabetes and overweight/obesity, and identify a subgroup with greater cardiovascular benefits from ILI. In a post-hoc analysis of the Look AHEAD trial, causal forest modeling was used to identify HTEs of ILI. The study population was stratified into four subgroups, and the associations of ILI with cardiovascular outcomes were assessed using multivariable Cox modeling compared to diabetes support & education (DSE). Among 4710 participants (mean age 58.9 years, 58.5% women), 768 primary outcomes occurred over a median follow-up of 9.5 years. Key variables identified through causal forest modeling were SF-36 mental health, diabetes duration, and urine albumin-creatinine ratio (ACR). In Subgroup 4 (SF-36 mental health > 55.64 and ACR > 10 mg/g), which had more cardiovascular risk factors and comorbidities, ILI significantly reduced the primary outcome risk (HR: 0.65, 95% CI: 0.48-0.87, P = 0.004) and three secondary outcomes compared to DSE. No cardiovascular benefits were observed in participants with SF-36 mental health ≤ 55.64 or ACR < 10 mg/g. This post-hoc analysis of the Look AHEAD trial showed HTEs of ILI in adults with type 2 diabetes and overweight/obesity. Participants with better mental health, poorer renal function, and more cardiovascular risk factors were more likely to benefit from ILI.
- 4 July 2026
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 16 (1)
Open AccessSubgroup-specific cardiovascular effects of intensive lifestyle intervention: a causal forest analysis in adults with type 2 diabetes and overweight/obesity
To evaluate the heterogeneity of treatment effects (HTEs) of intensive lifestyle intervention (ILI) in adults with type 2 diabetes and overweight/obesity, and identify a subgroup with greater cardiovascular benefits from ILI. In a post-hoc analysis of the Look AHEAD trial, causal forest modeling was used to identify HTEs of ILI. The study population was stratified into four subgroups, and the associations of ILI with cardiovascular outcomes were assessed using multivariable Cox modeling compared to diabetes support & education (DSE). Among 4710 participants (mean age 58.9 years, 58.5% women), 768 primary outcomes occurred over a median follow-up of 9.5 years. Key variables identified through causal forest modeling were SF-36 mental health, diabetes duration, and urine albumin-creatinine ratio (ACR). In Subgroup 4 (SF-36 mental health > 55.64 and ACR > 10 mg/g), which had more cardiovascular risk factors and comorbidities, ILI significantly reduced the primary outcome risk (HR: 0.65, 95% CI: 0.48-0.87, P = 0.004) and three secondary outcomes compared to DSE. No cardiovascular benefits were observed in participants with SF-36 mental health ≤ 55.64 or ACR < 10 mg/g. This post-hoc analysis of the Look AHEAD trial showed HTEs of ILI in adults with type 2 diabetes and overweight/obesity. Participants with better mental health, poorer renal function, and more cardiovascular risk factors were more likely to benefit from ILI.
- Open Access
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e035788
Intensive Glycemic Treatment Mitigates Cardiovascular and Mortality Risk Associated With Cardiac Autonomic Neuropathy in Type 2 Diabetes
Background: Hyperglycemia is one of the proposed risk factors for cardiac autonomic neuropathy (CAN). CAN is associated with increased cardiovascular and mortality risk. But it remains unclear whether cardiovascular and mortality risk associated with CAN is mitigated by intensive glycemic treatment. Methods and Results: This secondary analysis included 7866 patients from the ACCORDION (Action to Control Cardiovascular Risk in Diabetes Follow‐On) study. CAN was defined using ECG‐derived measures. End points included primary outcome (composite of cardiovascular events) and total deaths. During a median follow‐up of 8.9 years, a total of 1341 cardiovascular events and 1364 all‐cause deaths were ascertained. Compared with standard treatment, intensive treatment reduced risk of primary outcome and total deaths among patients with CAN but not among those without CAN. Compared with absence of CAN, the presence of CAN was associated with increased risk of primary outcome and total deaths in the standard group but not in the intensive group. Significant interactions were found between CAN status and treatment arms on risk of primary outcome and total deaths. Incidence rates per 100 person‐years of primary outcome and total deaths were similar between patients without CAN and those with CAN undergoing intensive treatment. Conclusions: Intensive glycemic treatment mitigates cardiovascular and mortality risk associated with CAN and may serve as an effective way in the management of CAN.
- 6 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (9) , e035788
Open AccessIntensive Glycemic Treatment Mitigates Cardiovascular and Mortality Risk Associated With Cardiac Autonomic Neuropathy in Type 2 Diabetes
Background: Hyperglycemia is one of the proposed risk factors for cardiac autonomic neuropathy (CAN). CAN is associated with increased cardiovascular and mortality risk. But it remains unclear whether cardiovascular and mortality risk associated with CAN is mitigated by intensive glycemic treatment. Methods and Results: This secondary analysis included 7866 patients from the ACCORDION (Action to Control Cardiovascular Risk in Diabetes Follow‐On) study. CAN was defined using ECG‐derived measures. End points included primary outcome (composite of cardiovascular events) and total deaths. During a median follow‐up of 8.9 years, a total of 1341 cardiovascular events and 1364 all‐cause deaths were ascertained. Compared with standard treatment, intensive treatment reduced risk of primary outcome and total deaths among patients with CAN but not among those without CAN. Compared with absence of CAN, the presence of CAN was associated with increased risk of primary outcome and total deaths in the standard group but not in the intensive group. Significant interactions were found between CAN status and treatment arms on risk of primary outcome and total deaths. Incidence rates per 100 person‐years of primary outcome and total deaths were similar between patients without CAN and those with CAN undergoing intensive treatment. Conclusions: Intensive glycemic treatment mitigates cardiovascular and mortality risk associated with CAN and may serve as an effective way in the management of CAN.
- Open Access
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2) , e034626
Sex Differences in the Association Between Cardiovascular Autonomic Neuropathy and Mortality in Patients With Type 2 Diabetes: The ACCORD Study
Background: Cardiovascular autonomic neuropathy (CAN) is a severe complication of type 2 diabetes. Significant sex‐related differences have been observed in type 2 diabetes consequences such as mortality. However, the effect of sex on the association between CAN and mortality in patients with type 2 diabetes is currently unknown. Methods and Results: We assessed 7866 participants in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, including 4730 men and 3136 women. CAN was diagnosed using a combination of heart rate variability and QT interval index, which has 3 different definitions. There were 1364 cases of all‐cause mortality and 452 cases of cardiovascular disease mortality during a median follow‐up of 9.7 years. We used multivariable Cox regression models to assess the association between different CAN definitions and mortality. In women, various CAN measures were statistically significant associated with an increased risk of all‐cause mortality (CAN1: hazard ratio [HR], 1.64 [95% CI, 1.28–2.09]; CAN2: HR, 1.58 [95% CI, 1.17–2.15]; CAN3: HR, 1.78 [95% CI, 1.20–2.65]) and mortality (CAN1: HR, 2.25 [95% CI, 1.44–3.52]; CAN 2: HR, 2.22 [95% CI, 1.28–3.87]; CAN3: HR, 3.31 [95% CI, 1.67–6.57]). CAN was not significantly associated with mortality in men. A significant multiplicative interaction of CAN and sex was observed on both mortality outcomes ( P <0.01). Conclusions: Significant sex‐related differences were observed in CAN and its associated mortality. In terms of mortality risk prevention, CAN should be given greater consideration in women with type 2 diabetes.
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2) , e034626
Open AccessSex Differences in the Association Between Cardiovascular Autonomic Neuropathy and Mortality in Patients With Type 2 Diabetes: The ACCORD Study
Background: Cardiovascular autonomic neuropathy (CAN) is a severe complication of type 2 diabetes. Significant sex‐related differences have been observed in type 2 diabetes consequences such as mortality. However, the effect of sex on the association between CAN and mortality in patients with type 2 diabetes is currently unknown. Methods and Results: We assessed 7866 participants in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, including 4730 men and 3136 women. CAN was diagnosed using a combination of heart rate variability and QT interval index, which has 3 different definitions. There were 1364 cases of all‐cause mortality and 452 cases of cardiovascular disease mortality during a median follow‐up of 9.7 years. We used multivariable Cox regression models to assess the association between different CAN definitions and mortality. In women, various CAN measures were statistically significant associated with an increased risk of all‐cause mortality (CAN1: hazard ratio [HR], 1.64 [95% CI, 1.28–2.09]; CAN2: HR, 1.58 [95% CI, 1.17–2.15]; CAN3: HR, 1.78 [95% CI, 1.20–2.65]) and mortality (CAN1: HR, 2.25 [95% CI, 1.44–3.52]; CAN 2: HR, 2.22 [95% CI, 1.28–3.87]; CAN3: HR, 3.31 [95% CI, 1.67–6.57]). CAN was not significantly associated with mortality in men. A significant multiplicative interaction of CAN and sex was observed on both mortality outcomes ( P <0.01). Conclusions: Significant sex‐related differences were observed in CAN and its associated mortality. In terms of mortality risk prevention, CAN should be given greater consideration in women with type 2 diabetes.
- 23 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (9) , 1173-1182
Prognostic significance of aortic valve calcification in relation to coronary artery calcification for cardiovascular diseases
Aims: Both coronary artery calcification (CAC) and aortic valve calcification (AVC) are strongly associated with cardiovascular diseases (CVDs), but data about the prognostic significance of multiple cardiovascular calcifications are limited. We aim to investigate the interaction relationship between AVC and CAC for major events. Methods and results: We included 6695 participants from the Multi-Ethnic Study of Atherosclerosis at baseline and divided them into four groups: (i) no AVC or CAC; (ii) only AVC; (iii) only CAC; and (iv) with CAC and CAC. The Cox regression model and the Kaplan–Meier method were used to analyse CVD outcomes. We evaluated the interaction between AVC and CAC and their added predictive value based on the pooled cohort equations (PCEs). Subgroup analyses were also explored. Among 6695 participants (mean age 62.2 ± 10.2 years, 47.2% male), after follow-up, 943 cases (14.1%) of CVD and 1274 cases (19.0%) of all-cause death occurred. For participants with both AVC and CAC, the risk of CVD significantly increased [hazard ratio = 3.43 (2.69–4.37), P < 0.001], even higher than the sum of the ones with only AVC and only CAC. This trend remained the same for all-cause death and among subgroup analyses. The addictive interaction was statistically significant (P < 0.001). When AVC and CAC were added, the predictive value of PCEs increased. Conclusion: Our results indicated a synergistic interaction between valve calcification and coronary calcification in CVDs. Management for both AVC and CAC may bring health co-benefits in preventing poor outcomes.
- 23 February 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (9) , 1173-1182
Prognostic significance of aortic valve calcification in relation to coronary artery calcification for cardiovascular diseases
Aims: Both coronary artery calcification (CAC) and aortic valve calcification (AVC) are strongly associated with cardiovascular diseases (CVDs), but data about the prognostic significance of multiple cardiovascular calcifications are limited. We aim to investigate the interaction relationship between AVC and CAC for major events. Methods and results: We included 6695 participants from the Multi-Ethnic Study of Atherosclerosis at baseline and divided them into four groups: (i) no AVC or CAC; (ii) only AVC; (iii) only CAC; and (iv) with CAC and CAC. The Cox regression model and the Kaplan–Meier method were used to analyse CVD outcomes. We evaluated the interaction between AVC and CAC and their added predictive value based on the pooled cohort equations (PCEs). Subgroup analyses were also explored. Among 6695 participants (mean age 62.2 ± 10.2 years, 47.2% male), after follow-up, 943 cases (14.1%) of CVD and 1274 cases (19.0%) of all-cause death occurred. For participants with both AVC and CAC, the risk of CVD significantly increased [hazard ratio = 3.43 (2.69–4.37), P < 0.001], even higher than the sum of the ones with only AVC and only CAC. This trend remained the same for all-cause death and among subgroup analyses. The addictive interaction was statistically significant (P < 0.001). When AVC and CAC were added, the predictive value of PCEs increased. Conclusion: Our results indicated a synergistic interaction between valve calcification and coronary calcification in CVDs. Management for both AVC and CAC may bring health co-benefits in preventing poor outcomes.
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e030132
Effect of Intensive Lifestyle Intervention on Cardiovascular Risk Factors: Analysis From the Perspective of Long‐Term Variability
Background: An association between variability of cardiovascular risk factors and cardiovascular events has been reported. We examined whether intensive lifestyle intervention (ILI) for weight loss decreased variability of cardiovascular risk factors with a view to additional cardiometabolic benefits. Methods and Results: This study was a post hoc secondary analysis of the Look AHEAD (Action for Health in Diabetes) study. Cardiovascular risk factors were measured at 1‐year intervals for 4 years in 4249 adults with overweight or obesity and type 2 diabetes who were randomly assigned to ILI or diabetes support and education. Long‐term variability was defined as the SD of cardiovascular risk factors during 4‐year follow‐up. At multiple linear regression analysis, compared with the diabetes support and education group, the ILI group was associated with reduced variability of fasting blood glucose (β=−1.49 [95% CI, −2.39 to −0.59]), total cholesterol (β=−1.12 [95% CI, −1.75 to −0.48]), and low‐density lipoprotein cholesterol (β=−1.04 [95% CI, −1.59 to −0.49]), as well as increased variability of systolic blood pressure (β=0.27 [95% CI, 0.00–0.54]). No significant effect of ILI was found on the variability of diastolic blood pressure (β=−0.08 [95% CI, −0.22 to 0.05]). Conclusions: Among adults with overweight or obesity and type 2 diabetes, ILI may reduce long‐term variability of fasting blood glucose, total cholesterol, and low‐density lipoprotein cholesterol. Our results support that ILI should be recommended to individuals with diabetes as part of management of long‐term glycemic and blood lipid control.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e030132
Open AccessEffect of Intensive Lifestyle Intervention on Cardiovascular Risk Factors: Analysis From the Perspective of Long‐Term Variability
Background: An association between variability of cardiovascular risk factors and cardiovascular events has been reported. We examined whether intensive lifestyle intervention (ILI) for weight loss decreased variability of cardiovascular risk factors with a view to additional cardiometabolic benefits. Methods and Results: This study was a post hoc secondary analysis of the Look AHEAD (Action for Health in Diabetes) study. Cardiovascular risk factors were measured at 1‐year intervals for 4 years in 4249 adults with overweight or obesity and type 2 diabetes who were randomly assigned to ILI or diabetes support and education. Long‐term variability was defined as the SD of cardiovascular risk factors during 4‐year follow‐up. At multiple linear regression analysis, compared with the diabetes support and education group, the ILI group was associated with reduced variability of fasting blood glucose (β=−1.49 [95% CI, −2.39 to −0.59]), total cholesterol (β=−1.12 [95% CI, −1.75 to −0.48]), and low‐density lipoprotein cholesterol (β=−1.04 [95% CI, −1.59 to −0.49]), as well as increased variability of systolic blood pressure (β=0.27 [95% CI, 0.00–0.54]). No significant effect of ILI was found on the variability of diastolic blood pressure (β=−0.08 [95% CI, −0.22 to 0.05]). Conclusions: Among adults with overweight or obesity and type 2 diabetes, ILI may reduce long‐term variability of fasting blood glucose, total cholesterol, and low‐density lipoprotein cholesterol. Our results support that ILI should be recommended to individuals with diabetes as part of management of long‐term glycemic and blood lipid control.
- 9 September 2023
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 99 (1) , 90-101
Intensive Glycemic Therapy in Type 2 Diabetes Patients With Cardiac Autonomic Dysfunction
- 9 September 2023
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 99 (1) , 90-101
Intensive Glycemic Therapy in Type 2 Diabetes Patients With Cardiac Autonomic Dysfunction
- 15 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , 581-591
Serum Klotho Modifies the Associations of 25-Hydroxy Vitamin D With All-Cause and Cardiovascular Mortality
Background: The association between 25-hydroxyvitamin D and mortality remains controversial. Klotho, a biomarker of vitamin D activation and metabolism, may play a key role in this association. However, it is unclear whether the association between vitamin D deficiency and mortality risk is modified by klotho levels. Therefore, this study investigated the joint association of serum 25-hydroxyvitamin D [25(OH)D] and klotho with mortality risk in American community-dwelling adults. Methods: A total of 9870 adults from the National Health and Nutrition Examination Survey (2007-2016) were included in our study. Mortality data were ascertained by linking participants to National Death Index records. Cox proportional hazards models were used to assess the association among serum 25(OH)D, serum klotho, and all-cause and cardiovascular disease (CVD) mortality. Results: We found a significant interaction between klotho and serum 25(OH)D in all-cause mortality (P = .028). With klotho > 848.4 pg/mL (risk threshold on mortality), no significant all-cause and CVD mortality risk was observed at any level of serum 25(OH)D. However, with klotho < 848.4 pg/mL, a significant all-cause and CVD mortality risk was observed with serum 25(OH)D < 50 nmol/L [hazards ratio (HR), 1.36; 95% confidence interval (CI), 1.10-1.69; HR, 1.78; 95% CI, 1.16-3.45) and serum 25(OH)D of continuous variable (HR, 0.98; 95% CI, .97-.99; HR, 0.98; 95% CI, .98-.99). In addition, vitamin D metabolism disruption accessed by the combination of decreasing serum 25(OH)D (<50 nmol/L) and klotho (<848.4 pg/mL) was associated with significant all-cause mortality (HR, 1.48; 95% CI, 1.11-1.96) and CVD mortality (HR, 2.36; 95% CI, 1.48-3.75). Conclusions: Vitamin D-associated mortality risk is observed only with concurrently decreasing klotho, indicating that vitamin D metabolism dysfunction increases the risk of mortality. Klotho levels could help predict long-term mortality outcomes and thus may be useful concurrently for guiding vitamin D supplementation therapy decision-making in populations with vitamin D deficiency.
- 15 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (2) , 581-591
Serum Klotho Modifies the Associations of 25-Hydroxy Vitamin D With All-Cause and Cardiovascular Mortality
Background: The association between 25-hydroxyvitamin D and mortality remains controversial. Klotho, a biomarker of vitamin D activation and metabolism, may play a key role in this association. However, it is unclear whether the association between vitamin D deficiency and mortality risk is modified by klotho levels. Therefore, this study investigated the joint association of serum 25-hydroxyvitamin D [25(OH)D] and klotho with mortality risk in American community-dwelling adults. Methods: A total of 9870 adults from the National Health and Nutrition Examination Survey (2007-2016) were included in our study. Mortality data were ascertained by linking participants to National Death Index records. Cox proportional hazards models were used to assess the association among serum 25(OH)D, serum klotho, and all-cause and cardiovascular disease (CVD) mortality. Results: We found a significant interaction between klotho and serum 25(OH)D in all-cause mortality (P = .028). With klotho > 848.4 pg/mL (risk threshold on mortality), no significant all-cause and CVD mortality risk was observed at any level of serum 25(OH)D. However, with klotho < 848.4 pg/mL, a significant all-cause and CVD mortality risk was observed with serum 25(OH)D < 50 nmol/L [hazards ratio (HR), 1.36; 95% confidence interval (CI), 1.10-1.69; HR, 1.78; 95% CI, 1.16-3.45) and serum 25(OH)D of continuous variable (HR, 0.98; 95% CI, .97-.99; HR, 0.98; 95% CI, .98-.99). In addition, vitamin D metabolism disruption accessed by the combination of decreasing serum 25(OH)D (<50 nmol/L) and klotho (<848.4 pg/mL) was associated with significant all-cause mortality (HR, 1.48; 95% CI, 1.11-1.96) and CVD mortality (HR, 2.36; 95% CI, 1.48-3.75). Conclusions: Vitamin D-associated mortality risk is observed only with concurrently decreasing klotho, indicating that vitamin D metabolism dysfunction increases the risk of mortality. Klotho levels could help predict long-term mortality outcomes and thus may be useful concurrently for guiding vitamin D supplementation therapy decision-making in populations with vitamin D deficiency.
- 22 May 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 30 (12) , 1263-1271
Body weight time in target range and cardiovascular outcomes in adults with overweight/obesity and type 2 diabetes
Aims: Prescription of weight loss to individuals is often characterized by weight fluctuations. However, current body weight management metrics may have difficulty characterizing the changes in body weight over time. We aim to characterize the long-term changes using body weight time in target range (TTR) and test its independent association with cardiovascular outcomes. Methods and results: We included 4468 adults from the Look AHEAD (Action for Health in Diabetes) trial. Body weight TTR was defined as the percentage of time during which body weight was within the Look AHEAD weight loss goal range. The associations of body weight TTR with cardiovascular outcomes were analysed using multivariable Cox modelling and restricted cubic spline function. Among the participants (mean age 58.9 years, 58.5% women, 66.5% White), there were 721 incident primary outcomes [cumulative incidence: 17.5%, 95% confidence interval (CI): 16.3–18.8%] during a median of 9.5 years of follow-up. Each 1 SD increase in body weight TTR was significantly associated with a decreased risk of the primary outcome (hazard ratio: 0.84, 95% CI: 0.75–0.94) after adjusting for mean and variability of body weight and traditional cardiovascular risk factors. Further analyses using restricted cubic spline indicated the inverse association between body weight TTR and the primary outcome in a dose-dependent manner. Similar associations remained significant among the participants with lower baseline or mean body weight. Conclusion: In adults with overweight/obesity and type 2 diabetes, higher body weight TTR was independently associated with lower risks of cardiovascular adverse events in a dose–response manner.
- 22 May 2023
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 30 (12) , 1263-1271
Body weight time in target range and cardiovascular outcomes in adults with overweight/obesity and type 2 diabetes
Aims: Prescription of weight loss to individuals is often characterized by weight fluctuations. However, current body weight management metrics may have difficulty characterizing the changes in body weight over time. We aim to characterize the long-term changes using body weight time in target range (TTR) and test its independent association with cardiovascular outcomes. Methods and results: We included 4468 adults from the Look AHEAD (Action for Health in Diabetes) trial. Body weight TTR was defined as the percentage of time during which body weight was within the Look AHEAD weight loss goal range. The associations of body weight TTR with cardiovascular outcomes were analysed using multivariable Cox modelling and restricted cubic spline function. Among the participants (mean age 58.9 years, 58.5% women, 66.5% White), there were 721 incident primary outcomes [cumulative incidence: 17.5%, 95% confidence interval (CI): 16.3–18.8%] during a median of 9.5 years of follow-up. Each 1 SD increase in body weight TTR was significantly associated with a decreased risk of the primary outcome (hazard ratio: 0.84, 95% CI: 0.75–0.94) after adjusting for mean and variability of body weight and traditional cardiovascular risk factors. Further analyses using restricted cubic spline indicated the inverse association between body weight TTR and the primary outcome in a dose-dependent manner. Similar associations remained significant among the participants with lower baseline or mean body weight. Conclusion: In adults with overweight/obesity and type 2 diabetes, higher body weight TTR was independently associated with lower risks of cardiovascular adverse events in a dose–response manner.